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Abstract
Background: Classical swine fever (CSF) or hog cholera is a highly contagious swine viral disease. CSF endemic countries
have to use routine vaccination with modified live virus (MLV) vaccines to prevent and control CSF. However, it is
impossible to serologically differentiate MLV vaccinated pigs from those infected with CSF virus (CSFV). The aim of this
study is to develop a one-dose E2-subunit vaccine that can provide protection against CSFV challenge. We hypothesize
that a vaccine consisting of a suitable adjuvant and recombinant E2 with natural conformation may induce a similar level
of protection as the MLV vaccine.
Results: Our experimental vaccine KNB-E2 was formulated with the recombinant E2 protein (Genotype 1.1) expressed
by insect cells and an oil-in-water emulsion based adjuvant. 10 pigs (3 weeks old, 5 pigs/group) were immunized
intramuscularly with one dose or two doses (3 weeks apart) KNB-E2, and 10 more control pigs were administered
normal saline solution only. Two weeks after the second vaccination, all KNB-E2 vaccinated pigs and 5 control pigs
were challenged with 5 × 105 TCID50 CSFV Honduras/1997 (Genotype 1.3, 1 ml intramuscular, 1 ml intranasal). It was
found that while control pigs infected with CSFV stopped growing and developed high fever (>40 °C), high level CSFV
load in blood and nasal fluid, and severe leukopenia 3–14 days post challenge, all KNB-E2 vaccinated pigs continued to
grow as control pigs without CSFV exposure, did not show any fever, had low or undetectable level of CSFV in blood
and nasal fluid. At the time of CSFV challenge, only pigs immunized with KNB-E2 developed high levels of E2-specific
antibodies and anti-CSFV neutralizing antibodies.
Conclusions: Our studies provide direct evidence that pigs immunized with one dose KNB-E2 can be protected clinically
from CSFV challenge. This protection is likely mediated by high levels of E2-specific and anti-CSFV neutralizing antibodies.
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Background
Classical swine fever (CSF) or hog cholera, causes severe
economic losses to the swine industry worldwide and pre-
sents a significant agro-security threat to CSF free coun-
tries such as the U.S. CSF is a highly contagious viral
disease of swine, including wild (feral) pigs. CSF is caused
by an enveloped Pestivirus named classical swine fever
virus (CSFV) [1]. The CSFV genome consists of a single,
positive-stranded RNA of approximately 12.3 kb encoding
a polyprotein of 3898 amino acids. The translated poly-
protein is processed by viral as well as cellular proteases
to the mature forms of four structural (C, Erns, E1, and
E2) and eight nonstructural viral proteins (Npro, p7, NS2,
NS3, NS4A, NS4B, NS5A, and NS5B) [2].
The genotypes of CSF viruses can be classified into
three major groups with eleven subgroups [3–5].
Group 1 (1.1, 1.2, 1.3, & 1.4) contains primarily his-
torical strains isolated from many regions of the
world and includes all live-attenuated vaccine strains.
Group 2 (2.1, 2.2, & 2.3) contains most of the cur-
rently circulating strains, whose prevalence has in-
creased and caused epidemic infection since the
1980s. Group 3 (3.1, 3.2, 3.3, & 3.4) contains most of
the strains distributed in separated geographic regions
such as Taiwan, Korea, Japan, Thailand and the
United Kingdom. Recent phylogenetic analyses have
indicated a “switch” of field CSFV from the historical
group 1 or 3 to the more recently prevalent group 2
in Europe and Asia [6, 7].
In contrast to the non-vaccination and stamping-out
policy in CSF-free zones, CSF endemic countries have to
use routine vaccination to prevent and control CSF.
When used properly, vaccination can be an effective ap-
proach to limit transmission of the CSFV, prevent dis-
ease outbreaks, and establish protective immunity in
naïve pig populations. To date, three types of CSF vac-
cines have been developed commercially: 1) modified
live virus (MLV) vaccines which are manufactured and
widely used in CSF endemic countries [8, 9]; 2) subunit
vaccines based on CSF viral envelope protein E2 [10–13]
, and 3) a chimeric live recombinant viral vector vaccine
[14–17]. Although they are important tools for CSF out-
break control, better CSF vaccines are needed for the
U.S. to maintain the CSF-free status because of the in-
trinsic limitations of the current commercial vaccines.
MLV CSF vaccines are generally safe and effective.
However, it is impossible to serologically differentiate
MLV vaccinated pigs from those infected with CSFV.
Thus, a long and costly non-vaccination and stamping-
out eradication process would have to be followed if
MLV are the only vaccines available. In addition, it
would be unsafe and costly to manufacture MLV vac-
cines in CSF-free countries such as the U.S. In 2015,
Suvaxyn CSF Marker, a chimeric CSF vaccine that
contains live bovine viral diarrhea virus (BVDV) which has
been modified to express CSF E2 gene was approved by the
European Union. However, Suvaxyn CSF Marker is ap-
proved only for emergency vaccination (page 6 in SUM-
MARY OF PRODUCT CHARACTERISTICS, http://
ec.europa.eu/health/documents/community-register/2016/
20160704135310/anx_135310_en.pdf).
Compared to MLV vaccines, subunit vaccines are de-
signed to meet the DIVA (differentiation of infected
from vaccinated animals) requirement for vaccination.
Two CSFV envelope glycoproteins Erns and E2 have
been targeted for vaccine development. Although the ef-
fectiveness of Erns as a vaccine target has been contro-
versial [18, 19], two vaccines (BAYOVAC CSF E2 from
Bayer and Porcilis Pesti from MSD) based on
baculovirus-expressed E2 were marketed commercially
in Europe. Vaccinated pigs develop antibodies exclu-
sively to the E2 protein; whereas, naturally infected
animals may also develop antibodies to Erns, thus per-
mitting detection of vaccinated animals via this negative
marker [20].
However, these subunit vaccines are no longer com-
mercially available because of two significant weaknesses
compared with conventional MLV CSF vaccines: they
need two vaccinations and offer incomplete protection.
In addition to insect cells, yeast and mammalian cells
are also used to produce E2 antigens for vaccine devel-
opment [18, 21]. However, two vaccinations are also re-
quired for these yeast- or mammalian cell-based E2
subunit vaccines to achieve homologous protection in
pigs. Despite the limitations of E2-subunit vaccines, E2
protein is well recognized as the protective antigen that
is essential and may be sufficient for vaccine-mediated
protection against CSFV.
One major objective of our CSF research is to develop
a DIVA CSF vaccine that can be safely manufactured
and used in the U.S. We have recently found that the
monoclonal anti-E2 antibody WH211 has much stronger
affinity to the dimeric E2 than the monomer. Others
have recently shown that antibodies specific to one
genotype E2 might not have strong affinity to other
genotype E2 proteins on CSFV [22], and this may
partially explain why limited protection against heterol-
ogous CSFV occurred in pigs vaccinated with E2-
subunit vaccines in which E2-specific antibodies play an
important role in protective immunity. In addition, we
have recently demonstrated that adjuvants can enhance
vaccine-mediated cross-protection against porcine re-
productive and respiratory syndrome virus (PRRSV) [23]
and swine influenza virus [24]. Thus, we hypothesize
that a vaccine consisting of a suitable adjuvant and re-
combinant E2 with natural conformation from the
C-strain may induce similar levels of protection as MLV
CSF vaccines. Here we provide the first evidence that
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pigs immunized with a novel one-dose E2-subunit vac-
cine (KNB-E2) are protected clinically from CSFV chal-
lenge. This protection is likely mediated by high levels of
E2-specific anti-CSFV neutralizing antibodies.
Methods
Virus and cells
Classical swine fever virus isolate Honduras/1997 (a field
isolate from Honduras) was kindly provided by Dr. Sabrina
Swenson from the Animal and Plant Health Inspection Ser-
vice (APHIS), United States Department of Agriculture
(USDA). This CSFV isolate was passaged four times in
swine testicle cells (ST; ATCC) cultured in DMEM (Gibco)
supplemented with 10 % fetal bovine serum (FBS; Atlanta
Biologicals) and 1 % Penicillin-streptomycin solution
(Gibco). For recombinant E2 production in insect cells,
Spodoptera frugiperda insect cells (Sf9; ATCC) were grown
in Grace’s insect medium (Gibco) supplemented with 10 %
FBS and 1 % antibiotic-antimycotic solution (Gibco), and
High Five insect cells (Invitrogen) were grown in Express
Five SFM medium (Gibco).
Expression and purification of recombinant CSFV E2 and
Erns protein
PCR-amplified CSFV E2 and Erns genes from hog cholera
lapinised virus C-strain (HCLV, Genotype 1.1) was cloned
into pFastBacTMI Baculovirus Expression System plasmid
vector using the following primers: HCLV-E2-F: 5′-
CGCGGATCCACCATAACCATTGCATTCCTCATC-3′,
HCLV-E2-R: 5′-CCGGAATTCTTAAT-GATGGTGATG
ATGCGCATCCAGGTCAAACCAG-3′; HCLV-Erns-F:
5′-CGCGGATCCACCATGGAAAAAGCCCTATT-GGC
ATG-3′, and HCLV-Erns-R: 5′-CCGGAATTCTTAATG
GTGATGGTGATGATGCACCCTCGCTGCTCCCTGT
C-3′. The desired PCR products were then transformed
into DH10BacTM E. coli host strain that contains a
baculovirus shuttle vector (bacmid) and a helper plasmid.
Upon screening of colonies, positive E. coli transformants
with recombinant E2 and Erns bacmid were upscaled by
overnight culture in liquid media and the bacmid was
isolated using Purelink® HiPure Plasmid Midiprep Kit
(Invitrogen). To generate recombinant baculovirus stock
for E2 and Erns expression, Sf9 insect cells were trans-
fected using Cellfectin II Reagent (Invitrogen) and pas-
saged three times to amplify the E2- or Erns bearing
recombinant baculovirus. At passage 3, Sf9 cell culture
supernatant was collected and clarified by centrifugation
at 500 × g for 5 min to obtain the baculovirus stock that
was used to infect High Five™ Cells for E2 or Erns expres-
sion. E2 and Erns protein was purified using Ni-NTA
Agarose (Novex™) as described by the manufacturer.
CSFV E2 protein expression and purification was verified
by SDS-PAGE and subsequently by western blot using E2
monoclonal antibody WH211 (APHA Scientific) as we de-
scribed previously [25].
Pigs, E2-subunit vaccine, vaccination, and challenge
Conventional Large White-Duroc crossbred weaned
specific-pathogen free male piglets (3 weeks of age) were
purchased from a commercial vendor. The pigs were fed
with standard commercial diet and kept under
laboratory biosafety level III Agriculture (BSL3-Ag) con-
ditions at the Biosecurity Research Institute (BRI),
Kansas State University.
The CSFV E2 subunit vaccine KNB-E2 was prepared by
simple hand mixing of purified CSFV E2 with an oil-in-
water emulsion adjuvant [24]. One dose (2 ml) KNB-E2
contains 75 μg of purified E2 protein. The pigs were ran-
domly allotted into 4 groups (n = 5 for each group) with
two control groups and two vaccinated groups. The con-
trol groups including non-vaccinated, non-challenged
(−/−) and non-vaccinated, CSFV challenged (−/+) pigs
were given intramuscularly 2 ml Phosphate-buffered saline
(PBS). All vaccinated pigs were immunized intramuscu-
larly with 2 ml of KNB-E2. One vaccinated group received
only one dose of the KNB-E2 (One-dose group) and the
second vaccinated group received two doses of KNB-E2
with the second dose given 21 days later (Two-dose
group). Two weeks after the second vaccination, pigs were
challenged with 5 × 105 TCID50 CSFV isolate Honduras/
1997 (1 ml intramuscular, 1 ml intranasal). Honduras/
1997 was evaluated as a moderate virulent strain in our
previous study. E2 sequencing and nucleotide BLAST ana-
lysis indicate that this isolate belongs to CSFV subgeno-
type 1.3 (GenBank Accession#: KU716076) and has 97 %
nucleotide sequence identity to a CSFV isolated in nearby
Guatemala (Accession # JX028200).
Pigs were monitored daily for clinical signs and rectal
temperatures. Sera were collected on study day 0 (Dose 1)
and 21 days post first vaccination (21 DPV; Dose 2).
Whole blood, serum and nasal swabs were collected on 35
DPV (also as 0 DPC) and every 3 days after challenge until
the end of this study, at 15 days post challenge (15 DPC).
All pigs that survived were humanely euthanized at 15
DPC. Total white blood cell (WBC) and leukocyte differ-
entiation counts were performed with VetScan HM5
Analyzer (Abaxis). Tonsil, lymph node, kidney, and lung
were collected for virus identification by immunohisto-
chemical staining with anti-E2 antibody WH303 as de-
scribed earlier with some modification [26].
Measurement of anti-E2 and anti-Erns antibodies in pigs
Anti-E2 and anti-Erns antibodies were determined in E2-
vaccinated and CSFV-infected pig sera by enzyme-linked
immunosorbent assay (ELISA). Briefly, 62.5 ng/ml of puri-
fied E2 or Erns was used as coating antigen on 96-well
flat-bottomed microtiter plates (Corning®). Diluted sera
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(each sample in duplicate) were added to plates and incu-
bated for 1 h at room temperature. Then, horseradishper-
oxidase (HRP)-conjugated goat anti-porcine IgG was used
as secondary antibody (Southern Biotech). The ELISA
plates were developed using 3,3,5,5 tetramethylbenzidine
(TMB) stabilized chromogen (Novex™), and the reactions
were stopped with 2 N sulfuric acid. Relative antibody
concentrations were determined using optical spectropho-
tometer readings at 450 nm using a SpectraMAX micro-
plate reader and analyzed with Softmax® Pro 6.4 Software
(Molecular Devices).
RNA isolation and real-time RT-PCR for virus quantifica-
tion in sera and nasal swabs
Viral RNA from sera and nasal swabs were isolated using
IBI Viral Nucleic Acid Extraction Kit II (IBI Scientific) as
prescribed by the manufacturer. Real-time RT-PCR was
performed using CSFV-specific primers and PCR cycling
parameters as previously described [27]. For quantification,
passage 4 CSFV stock (107 TCID50) was serially diluted
(107 to 102) before viral RNA isolation and used for stand-
ard curve. Viremia was calculated and determined using
StepOne™ Software v2.3 (Applied Biosystems).
Serum anti-CSFV neutralization assay
The anti-CSFV neutralizing antibody titers in the serum
were determined using indirect fluorescent antibody assay
(IFA). Briefly, serum samples collected at 35 DPV (0 DPC)
and 15 DPC were first diluted five-fold and then serially
diluted two-fold, the diluted serum samples (in duplicate)
were incubated with 100 TCID50 of CSFV Honduras/1997
in DMEM with 10 % FBS for 1 h at 37 °C. Residual virus
infectivity was determined by adding 1.0 × 104 ST cells to
each well with serum-virus mixture in 96-well plate and
incubated at 37 °C for 3 days. The cells were subjected to
Fig. 1 Production and characterization of recombinant CSFV E2 protein.
a SDS-PAGE analysis. Lane 1, E2 protein (1 μg) treated with Laemmli
sample buffer with addition of reducing reagent β-mercaptoethanol
(β-ME); Lane 2, E2 protein (1 μg) treated with Laemmli sample buffer
without β-ME. bWestern blot of purified E2 protein. Lane 1, E2 protein
(1 μg) treated with β-ME; Lane 2, E2 protein (50 ng) purified and stored
under non-reducing conditions. E2-specific Mab WH211 was used for
the western blot
Fig. 2 Pigs immunized with E2 subunit vaccine KNB-E2 were protected
clinically from CSFV challenge. Pigs were immunized with KNB-E2 on
Day 0 for the One-dose group and a second dose on 21 DPV for the
Two-dose group. Two weeks after the second vaccination (35 DPV), pigs
were challenged with 5 × 105 TCID50 CSFV strain Honduras/1997. a Body
temperature was monitored daily after CSFV infection. Vaccinated pigs
did not have body temperatures higher than 40.5 °C. b Shown are body
weight measured every 3 days after CSFV challenge. Data are mean ±
SEM for five pigs per group. * p< 0.05
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immunofluorescence staining with E2-specific mAb
WH211 and Alexa Fluor 488 goat anti-mouse IgG (H + L)
(Life Science). Neutralizing antibody titers in serum sam-
ples were expressed as the reciprocal of the highest dilu-
tion that caused 50 % neutralization.
Statistical analysis
The variations between groups were analyzed by one-way
analysis of variance (ANOVA) followed by post-hoc Dun-
nett’s method using Sigmaplot 11 software (Systat). Differ-
ences were considered statistically significant when p < 0.05.
Results
Recombinant CSFV E2 proteins produced by insect cells
existed as homodimers and had stronger affinity to anti-
E2 antibody than that of the monomeric E2 proteins
CSF virus E2 gene from the HCLV was cloned into the
recombinant baculovirus and recombinant E2 protein
was produced using High Five insect cells. The culture
medium was then collected by centrifugation and sub-
jected to protein purification with Ni-NTA agarose
beads. As shown in Fig. 1a, pure recombinant E2 protein
was obtained from the condition medium. Under redu-
cing conditions, recombinant E2 protein appeared to be
45 kDa, while the native E2 protein mainly existed as
homodimer under non-reducing conditions with a
molecular weight of ~90 kDa (Fig. 1a). The dimerization
of recombinant E2 protein expressed in insect cells was
further confirmed by western blot analysis with anti-E2
mAb WH211. It is worth noting that although the
amount of E2 dimer protein loaded in lane 2 on Fig. 1b
was only 1/20 of the monomeric E2 (50 ng vs. 1 μg), E2
dimers seem to have a higher affinity to WH211 than
did the E2 monomer as evidenced by the difference in
intensity of the E2 bands on western blot (Fig. 1b).
Pigs immunized with one dose KNB-E2 were protected
from heterologous CSFV challenge
To test the efficacy of CSFV E2 subunit vaccine, pigs in
both vaccinated groups and the (−/+) group were chal-
lenged with CSFV isolate Honduras/1997. After CSFV
inoculation, pigs in the (−/+) group displayed clinical
signs of CSF, including high fever (Fig. 2a), loss of body
weight (Fig. 2b), severe leukopenia (Fig. 3), convulsion,
diarrhea, and one of the five pigs, #59, had to be eutha-
nized due to severe clinical symptoms at 9 DPC. In con-
trast, pigs vaccinated with KNB-E2 - the E2 subunit
vaccine (One-dose and Two-dose groups) did not show
elevated body temperature after CSFV challenge (Fig. 2a).
More importantly, body weight gains in the two vacci-
nated groups were almost identical to that in healthy
Fig. 3 Pigs vaccinated with KNB-E2 were protected from CSFV-induced leukopenia. Blood cell counts including WBC (a), lymphocytes (b),
neutrophils (c), and monocytes (d) were monitored on 0, 3, 6, 9, 12, and 15 DPC. A slight decrease but not statistically different in the numbers of
WBC, lymphocytes, and neutrophils of all vaccinated pigs were observed at 3 DPC and 6 DPC, these numbers were recovered by 9 DPC. Data are
mean ± SEM for five pigs per group. *p < 0.05
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control pigs (−/−) before and after CSFV challenge
(Fig. 2b).
WBC and lymphocyte counts in (−/+) pigs challenged
with CSFV were significantly reduced after CSFV inocula-
tion and reached the lowest levels at 9 DPC (Fig. 3a and b),
respectively. In contrast, there was a slight decrease in the
numbers of WBC and lymphocytes in pigs vaccinated with
KNB-E2 at 3 and 6 DPC; however, the numbers of these
cells in vaccinated pigs, especially for pigs in the One-dose
group, increased significantly at 9 DPC and then after
(Fig. 3a and b, respectively). Similarly, the numbers of neu-
trophils in the (−/+) group were significantly reduced at 9
and 12 DPC (Fig. 3c), while the numbers of neutrophils in
pigs immunized with KNB-E2 were increased significantly
at 9 and 12 DPC. The numbers of monocytes in all pig
groups seem not to be affected significantly by the CSFV
challenge (Fig. 3d).
Vaccination prevents CSF virus replication in blood, nasal
cavity, lung, lymph node, tonsil, and kidney in pigs
immunized with KNB-E2
CSFV was detected in both serum and nasal swab sam-
ples from the (−/+) pigs at 6 DPC. The virus loads in
these pigs continued to increase at 9 and 12 DPC and re-
duced slightly at the time of necropsy on 15 DPC (Tables 1
and 2). In contrast, pigs vaccinated KNB-E2 (One-dose or
Two-dose) had undetectable or extremely low levels of
CSFV RNA in the blood and nasal fluids by real-time RT-
PCR analysis (Tables 1 and 2). CSFV was not detected in
any of the serum samples from KNB-E2 vaccinated pigs
when they were added to ST cells (10 μl/well in a 96-well
plate) for virus isolation (data not shown); and using the
same method, CSFV was detected in serum samples from
(−/+) pigs collected on 6 and 9 DPC (data not shown).
Surprisingly, one of the (−/+) pigs, #56, had significantly
less CSFV in the blood and nasal fluid than that of other
pigs in the (−/+) group.
Using immunohistochemical staining with E2-specifc
antibody WH303, we also determined whether CSFV
were present in the lung, lymph nodes, kidney, and
tonsil collected from all groups at necropsy (15 DPC).
It was found that CSFV were present in the tonsil,
lymph node, lung, and kidney in 4/5 of the (−/+) pigs
(data not shown). Consistent with the real-time RT-
PCR data shown above, CSFV was not detected in
any of the tissues from pig #56. CSFV was not
Table 1 Pigs vaccinated with E2 subunit vaccine did not develop viremia after CSFV challenge
Serum 3 DPC 6 DPC 9 DPC 12 DPC 15 DPC
Treatment Pig # Ct value TCID50 Ct value TCID50 Ct value TCID50 Ct value TCID50 Ct value TCID50
(−/−) 51 (−) (−) ND ND ND ND ND ND ND ND
(−/−) 52 37 98 ND ND ND ND (−) (−) (−) (−)
(−/−) 53 (−) (−) (−) (−) ND ND (−) (−) 36 112
(−/−) 54 (−) (−) (−) (−) (−) (−) (−) (−) (−) (−)
(−/−) 55 (−) (−) (−) (−) (−) (−) (−) (−) (−) (−)
(−/+) 56 (−) (−) 29 4330 30 2774 28 17,617 35 163
(−/+) 57 36 78 25 47,547 20 1,460,325 19 4,993,009 21 1,036,940
(−/+) 58 (−) (−) 28 7090 23 222,328 20 2,587,042 21 1,095,457
(−/+) 59 (−) (−) 26 28,553 22 480,384 pig died
(−/+) 60 (−) (−) 29 5169 22 507,102 21 1,019,529 21 1,003,013
One-dose 61 37 42 28 7192 35 160 38 29 38 58
One-dose 62 (−) (−) 34 170 (−) (−) 39 21 (−) (−)
One-dose 63 34 179 35 160 36 68 (−) (−) (−) (−)
One-dose 64 36 56 33 330 34 169 36 131 (−) (−)
One-dose 65 (−) (−) 35 100 (−) (−) (−) (−) (−) (−)
Two-dose 66 (−) (−) 36 56 35 106 (−) (−) (−) (−)
Two-dose 67 (−) (−) 34 279 (−) (−) (−) (−) (−) (−)
Two-dose 68 (−) (−) 36 85 (−) (−) (−) (−) (−) (−)
Two-dose 69 (−) (−) (−) (−) (−) (−) (−) (−) (−) (−)
Two-dose 70 (−) (−) 35 97 (−) (−) (−) (−) (−) (−)
ND not done; (−): Undetectable; Pigs were challenged with CSFV 35 days post first vaccination. CSFV RNA in the blood was measured by real-time RT-PCR as
described in Methods section
(−/−): Control pigs without CSFV challenge; (−/+): Control pigs challenged with CSFV
One-dose: Pigs vaccinated with one dose KNB-E2 and then challenged with CSFV
Two-dose: Pigs vaccinated with KNB-E2 twice and then challenged with CSFV
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detected in any tissues from pigs vaccinated with
KNB-E2 (One-dose or Two-dose).
Pigs vaccinated with KNB-E2 developed high levels of E2-
specific antibodies and anti-CSFV neutralizing antibody
(VNA) titers after vaccination and challenge
As shown in Fig. 4a, all vaccinated pigs developed
E2-specific antibody after immunization. E2-specific
antibody level in the One-dose group increased dramat-
ically after challenge and was even higher than that in
the Two-dose group at 9 DPC. The level of E2-specific
antibody in the Two-dose group increased dramatically
after the boost vaccination, but decreased significantly in
the first 9 days post challenge. E2-specific antibody was
not detected in control pigs before or after the challenge
(Fig. 4a). In contrast to E2-spepcific antibody response,
Erns-specific antibody was only detected in the (−/+) pigs
at 15 DPC (Fig. 4b).
Similar to E2-specific antibody response, all vaccinated
pigs developed anti-CSFV neutralizing antibody before
challenge at 35 DPV (Table 3). The VNA titers in the
One-dose group were lower than that in the Two-dose
group at 35 DPV. However, the VNA titers in the
One-dose group were higher than that in the Two-dose
group at 15 DPC. Pigs in the control groups had no de-
tectable neutralizing antibody at 35 DPV and 15 DPC.
Thus, there seems to be close correlation between
anti-CSFV neutralizing antibody titers and levels of
E2-specific antibodies in pigs after KNB-E2 vaccination
and CSFV challenge. Consistent with its viremia status,
pig #56 in the (−/+) group had detectable anti-CSFV
neutralizing antibody at 15 DPC.
Discussion
Commercial E2 subunit vaccines previously available in
Europe were marketed as two-dose vaccines for basic
vaccination for homologous protection. Here we present
data showing that vaccination with one dose KNB-E2
protects pigs from subgenotype heterologous (1.1 vs. 1.3)
CSFV challenge. Pigs vaccinated with KNB-E2 did not have
any fever or growth retardation after CSFV challenge. CSFV
was not detected in the blood, nasal cavity, lung, kidney,
lymph node, and tonsil in vaccinated pigs 15 days post chal-
lenge. Our report demonstrates that subunit vaccine KNB-
E2 is safe and effective at stimulating immunity against
Table 2 CSFV were cleared from the nasal cavity in pigs vaccinated with E2 subunit vaccine 15 days post challenge
Nasal swab 3 DPC 6 DPC 9 DPC 12 DPC 15 DPC
Treatment Pig # Ct value TCID50 Ct value TCID50 Ct value TCID50 Ct value TCID50 Ct value TCID50
(−/−) 51 ND ND ND ND ND ND ND ND (−) (−)
(−/−) 52 ND ND ND ND ND ND (−) (−) (−) (−)
(−/−) 53 (−) (−) (−) (−) (−) (−) (−) (−) (−) (−)
(−/−) 54 (−) (−) (−) (−) 39 37 (−) (−) (−) (−)
(−/−) 55 (−) (−) 34 184 34 560 (−) (−) (−) (−)
(−/+) 56 (−) (−) 35 95 33 1521 28 19,033 33 2867
(−/+) 57 (−) (−) 32 876 24 300,220 20 1,882,476 22 904,988
(−/+) 58 37 31 34 293 24 411,326 21 1,438,113 21 1,502,256
(−/+) 59 (−) (−) 32 1065 21 3,182,081 pig died
(−/+) 60 38 19 34 261 25 293,326 21 1,451,296 22 745,304
One-dose 61 (−) (−) 35 124 36 166 36 106 (−) (−)
One-dose 62 (−) (−) (−) (−) 38 52 37 42 36 109
One-dose 63 (−) (−) 37 35 37 83 33 495 (−) (−)
One-dose 64 (−) (−) 34 224 (−) (−) 37 68 (−) (−)
One-dose 65 (−) (−) 36 68 37 78 34 301 (−) (−)
Two-dose 66 (−) (−) 37 38 39 28 35 145 (−) (−)
Two-dose 67 (−) (−) 36 60 38 67 35 221 (−) (−)
Two-dose 68 (−) (−) (−) (−) 34 2398 34 283 (−) (−)
Two-dose 69 (−) (−) 36 56 37 79 34 269 37 42
Two-dose 70 (−) (−) 36 58 (−) (−) 34 330 (−) (−)
ND not done; (−): Undetectable; Pigs were challenged with CSFV 35 days post first vaccination. CSFV RNA in the blood was measured by real-time RT-PCR as
described in Methods section
(−/−): Control pigs without CSFV challenge; (−/+): Control pigs challenged with CSFV
One-dose: Pigs vaccinated with one dose KNB-E2 and then challenged with CSFV
Two-dose: Pigs vaccinated with KNB-E2 twice and then challenged with CSFV
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heterologous and geographically (Central-South America)
relevant CSFV in an experimental setting in the U.S.
It has been well established that CSFV E2 protein is
the major protective antigen and can elicit neutralizing
antibody, thus it is frequently used as the antigen for
subunit vaccine development (see reviews [6, 9, 28]).
Because attenuated CSFV vaccine HCLV strain is well-
known for its efficacy and safety, the HCLV E2 gene
(genotype 1.1) was cloned and expressed with the insect
cell/baculovirus system in this study. Purified E2 pro-
teins mainly present as homodimers, which is identical
to the native glycosylated E2 protein reported in previ-
ous studies [21, 29]. Furthermore, we found that E2
homodimers have higher affinity to E2-specific mAb
WH211 than do the monomers, indicating that
oligomerization and glycosylation of E2 protein are
important for the induction of protective immune
response and neutralizing antibodies.
The efficacy of the two commercial E2 subunit vac-
cines has been extensively evaluated in various
vaccination-challenge studies in pigs. The E2 antigen in
BAYOVAC CSF E2 was originated from CSF Brescia
[30], a genotype 1.2. Although a single vaccination with
this vaccine can significantly reduce mortality of pigs
challenged with homologous CSFV up to 13 months
after a single vaccination [13], it did not protect pigs
from developing fever [11]. Different from BAYOVAC
CSF E2, the E2 antigen in Porcilis Pesti was originated
from CSFV Alfort/Tubingen [28], a genotype 2.3. It was
reported that single vaccination with Porcilis Pesti failed
to protect immunized pigs and prevent horizontal trans-
mission of CSFV (Alfort/187, genotype 1.1) to unvaccin-
ated sentinel pigs [31]. Others have shown that Porcilis
Pesti can totally prevent horizontal transmission 14 DPV
and significantly reduce transmission 7 DPV [10].
In contrast, pigs immunized with one dose KNB-E2
are protected from a subgenotype heterologous CSFV
challenge without the development of fever and growth
retardation, and CSFV was cleared from the pigs by 15
DPC. The differential efficacy between KNB-E2 and the
commercial E2 subunit vaccines may be due to the fact
that we use E2 protein from genotype 1.1 C-strain CSFV
and/or the E2 antigens in KNB-E2 are in the native
dimeric conformation. This speculation is consistent
with the report from others showing that sows vacci-
nated with E2 proteins from CSFV genotype 1.2 were
better protected against clinical CSF than sows vacci-
nated with E2 proteins from CSFV genotype 2.3 when
these pigs were challenged with CSFV genotype 2.1 [32].
Alternatively, the higher (75 μg/dose for KNB-E2 vs.
32 μg/dose for BAYORVAC CSF E2) amount of E2 pro-
tein used in our vaccine may also contribute to the su-
perior efficacy after one dose immunization.
In addition, we have also found that pigs immunized
with one dose or two doses of KNB-E2 have different
antibody responses to CSFV challenge. Prior to chal-
lenge, the VNA titer and E2-specific antibody in pigs
from the One-dose group were lower than that from
pigs in the Two-dose group (Table 3 and Fig. 4). How-
ever, pigs in the One-dose group generated higher anti-
CSFV neutralizing antibody and E2-specific antibody
after challenge than that of pigs in the Two-dose group.
It seems that CSFV challenge with Honduras/1997 may
function as a booster vaccination with live viruses, which
resulted in the induction of a stronger immunological
response and a larger amounts of neutralizing antibody
than does a boost vaccination with a subunit vaccine.
We speculate that the high levels of VNA and E2-spe-
cific antibodies prior to challenge in the Two-dose pigs
may accelerate the inactivation and removal of
Fig. 4 E2-specific antibodies were detected by ELISA only in pigs
vaccinated with KNB-E2 before and after challenge. E2- and Erns-specific
antibodies were measured by ELISA as we described in Materials and
Methods. a E2-specific antibody in serum samples collected after
vaccination and challenge. b Erns-specific antibody in serum samples
collected at 0 DPC and 15 DPC. Data are shown as mean ± SEM for five
pigs per group. * p < 0.05
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circulating CSFV post challenge, which may lead to
fewer or no live CSFV available for further immuno-
logical stimulation.
The dynamics of anti-CSFV neutralizing antibody pro-
duced in the vaccinated groups after challenge is consist-
ent with the changes of white blood cells. As shown in
Figs. 3 and 4, the trends (decrease or increase) of WBC
and lymphocytes parallel the trends of E2-specific anti-
body levels and VNA titers in vaccinated pigs compared
with that in control pigs. Interestingly, the impact of
KNB-E2 vaccination on leukocyte homeostasis is differ-
ent from that of MLV C-strain vaccine, as evidenced by
the fact that dramatic increase of leukocyte cells in pigs
vaccinated with KNB-E2 was not observed in pigs im-
munized with the C-strain vaccine [33]. The meaning of
this difference has yet to be explored in future studies.
In contrast to all vaccinated pigs, control pigs chal-
lenged with CSFV developed significant levels of anti-
Erns antibody at 15 days post challenge. This observation
indicates that KNB-E2 has the DIVA characteristic as a
CSF vaccine. However, we do recognize that although
the challenge CSFV strain Honduras/1997 used in our
study is from the Americas and heterologous to the ori-
gin strain of the E2 gene, it is not a recent outbreak
strain. Our study design was limited by the current avail-
ably of CSFV in an academic setting in the U.S. – a
CSF-free country. Because most of the presently circu-
lating strains in the world belong to genotype 2, future
studies are planned to better understand the protective
ability of KNB-E2 against the CSFV in the field.
Conclusion
CSFV E2 protein was successfully generated by insect
cell/baculovirus expression system and the purified E2
protein was formulated with an oil-in-water emulsion
adjuvant as a CSF subunit vaccine (KNB-E2) for pigs.
Pigs immunized with one dose KNB-E2 can be clinically
protected from CSFV challenge. This novel subunit vac-
cine has DIVA characteristics, can be manufactured in
CSF-free regions, and is suitable for CSF prevention and
control in both CSF endemic area and emergency
outbreaks.
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DPV day post vaccination (first dose), DPC day post challenge. Pigs were challenged on 35 DPV
(−/−): Control pigs without challenge; (−/+): Control pigs challenged with CSFV
One-dose: Pigs vaccinated with one dose KNB-E2 and then challenged with CSFV
Two-dose: Pigs vaccinated with KNB-E2 twice and then challenged with CSFV
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